3 completed, 2 active not recruiting, 2 terminated. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Active not recruiting 2, Terminated 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Non-cystic Fibrosis Bronchiectasis: new trials by email Literature Review of Non-cystic Fibrosis Bronchiectasis trials Research Report on Non-cystic Fibrosis Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa Rev-56 for Inhalation, Placebo: Normal saline - Healthy Participants, Non-cystic Fibrosis Bronchiectasis | Phase 1 | Active not recruiting | Revagenix, Inc. | 64 | 2026-07-13 | 2026-10-14 |
| A Clinical Study of RSS0343 in Healthy Subjects RSS0343 Tablets, RSS0343 Tablets Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 1 | Completed | Reistone Biopharma Company Limited | 48 | 2026-01-08 | 2026-08-17 |
| A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease GDC-6988 - Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Genentech, Inc. | 17 | 2024-11-18 | 2026-10-20 |
| Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) RESP302, RESP303 - Non-Cystic Fibrosis Bronchiectasis | Phase 1 / Phase 2 | Active not recruiting | Thirty Respiratory Limited | 60 | 2024-10-16 | 2026-03-10 |
| A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation BI 1323495, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 1 | Terminated | Boehringer Ingelheim | 7 | 2021-03-04 | 2024-11-27 |
| A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis CHF 6333, Placebo - Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 68 | 2019-05-27 | 2021-03-30 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects CHF6333 (Part 1 - SAD), Placebo (Part 1 - SAD), CHF6333 (Part 2 - MAD) - Non-Cystic Fibrosis Bronchiectasis, Cystic Fibrosis | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 72 | 2016-11-01 | 2017-11-07 |
Cystic Fibrosis (2) · Pulmonary Disease, Chronic Obstructive (1)
Lung Diseases (3) · Respiratory Tract Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Genetic Diseases, Inborn (2) · Infant, Newborn, Diseases (2) · Pancreatic Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Lung Diseases, Obstructive (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Inhalation (1)
Chiesi Farmaceutici S.p.A. (2) · Boehringer Ingelheim (1) · Genentech, Inc. (1) · Reistone Biopharma Company Limited (1) · Revagenix, Inc. (1) · Thirty Respiratory Limited (1)
Germany (2) · United States (2) · Belgium (1) · China (1) · Ukraine (1)
2015 (1), 2018 (1), 2019 (1)